Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 27, 2021

Primary Completion Date

December 30, 2021

Study Completion Date

July 11, 2023

Conditions

Extensive Stage Lung Small Cell CarcinomaMalignant Solid NeoplasmMetastatic Malignant Neoplasm in the Brain

Interventions

BIOLOGICAL

Atezolizumab

Given IV

DRUG

Carboplatin

Given IV

DRUG

Entinostat

Given PO

DRUG

Etoposide

Given IV

Trial Locations (5)

Memorial Sloan Kettering Cancer Center, New York

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

University of Virginia Cancer Center, Charlottesville

University of Wisconsin Carbone Cancer Center, Madison

Huntsman Cancer Institute/University of Utah, Salt Lake City

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH